Article

Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models

2024-01-11

Abstract excerpt

<title>Abstract</title> B-cell maturation antigen (BCMA) plays a pathobiologic role in myeloma and is a validated target with five BCMA-specific therapeutics having been approved for relapsed/refractory disease. However, these drugs are not curative, and responses are inferior in patients with molecularly-defined high-risk disease, including those with deletion 17p (del17p) involving the tumor suppressor <ital...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: df82f3f1-3f6d-5cb8-a250-4086151cafce
DOI: 10.21203/rs.3.rs-3843028/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma ModelsDOI 10.21203/rs.3.rs-3843028/v1Read

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read

Multi-omic and functional screening reveal targetable vulnerabilities inTP53mutated multiple myelomaSemantic proximity Read

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or DeletedTP53Semantic proximity Read

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocationSemantic proximity Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroupsSemantic proximity Read

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MMSemantic proximity Read

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Semantic proximity Read

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read